Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Blinatumomab by Amgen for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Pre-Registration for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According...
Blinatumomab by Amgen for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData,...
Blinatumomab by Amgen for Lymphoblastic Lymphoma: Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase III for Lymphoblastic Lymphoma. According to GlobalData, Phase III...
Blinatumomab by Amgen for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase III for Splenic Marginal Zone B-Cell Lymphoma. According to...
Blinatumomab by Amgen for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase III for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...
Blinatumomab by Amgen for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase III for Nodal Marginal Zone B-Cell Lymphoma. According to...
Blinatumomab by Amgen for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData,...
Blinatumomab by Amgen for Follicular Lymphoma: Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III...